Cardiovascular atherosclerotic diseases represent the main cause of death in the developed and developing populations. Although major progress has been made in the management of the classical modifiable cardiovascular risk factors, unhealthy lifestyle conduces to an increasing prevalence of overweight, obesity, metabolic disorders, type 2 diabetes mellitus, premature atherosclerosis and cardiovascular diseases. That is why cardio-metabolic risk prediction should be superior in the primary prevention of atherosclerosis and cardiovascular diseases. Up-to-date primary preventive strategies according to the European Guidelines, especially the high risk strategy approach, are being implemented. Individual cardiovascular and better cardio-metabolic risk assessment represents the basic approach in the individualized primary prevention of cardiovascular diseases and type 2 diabetes mellitus. Cardio-metabolic biomarkers, especially high sensitivity C-reactive protein, albuminuria, N-terminal pro-brain natriuretic peptide, and imaging procedures (carotid intima-media thickness measured by ultrasound) could improve the prediction of cardiovascular diseases and type 2 diabetes beyond that using traditional risk factors.

Centre of Preventive Cardiology of the 2nd Medical Department University Hospital E Benese 13 305 99 Pilsen Czech Republic

Zobrazit více v PubMed

Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: WHO, Dec 2009. Assessed at: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf

http://data.euro.who.int/hfadb

Graham I, Atar D, Borch-Johnsen K, et al. Task Force Members: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl.2):E1–40. PubMed

Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937–42. PubMed

Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2004;364:937–52. PubMed

Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. Diabetologia. 1990;33:542–8. PubMed

Research Group of MRFIT Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial. Am J Cardiol. 1986;58:1–13. PubMed

Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J., 3rd Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50. PubMed

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607. PubMed

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5. PubMed

The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) of the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007;28:88–136. PubMed

Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. PubMed

Cifkova R, Byma S, Ceska R, et al. Prevention of cardiovasclar diseases in adults. Task force of the Czech medical societies. Vnitr Lek. 2005;51(9):1021–36.

Kahn R, Buse J, Ferrannini E, Stern M. American diabetes association; European Association for the study of diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care. 2005;28:2289–304. PubMed

Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr. 1956;4:20–34. PubMed

Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small dense LDL) in men. Circulation. 2000;102:179–84. PubMed

Lamarche B, Tchemof A, Mauriége P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955–61. PubMed

Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–7. PubMed

Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8. PubMed PMC

Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A condensed position paper by the Residual Risk Reduction Initiative (R3I) Diab Vasc Dis Res. 2008;5:319–35. PubMed

Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass pattern and risk of myocardial infarction. JAMA. 1988;260:1917–21. PubMed

Sacks FM, Expert Group on HDL Cholesterol The role of high-density lipoprotein (HDL) in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002;90:139–43. PubMed

Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8. PubMed

Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest. 2007;37:925–32. PubMed

McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802–9. PubMed

Dobiasova M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50:1113–5. PubMed

Dobiasova M. AIP atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to clinical practice. Vnitr Lék. 2006;52:64–71. PubMed

The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74. PubMed PMC

Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. PubMed PMC

Balkau B, Hu G, Qiao Q, et al. DECODE Study Group, European Diabetes Epidemiology Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47:2118–28. PubMed

Saaristo T, Peltonem M, Lindstrom J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance, and metabolic syndrome. Diab Vasc Dis Res. 2005;2:67–72. PubMed

Rosolova H, Petrlova B, Simon J, Sifalda P, Sipova I. High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome. Med Sci Monit. 2008;14:CR411–5. PubMed

The Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40. PubMed PMC

Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97:3A–11. PubMed

Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis and treatment. Clin J Am Soc Nephrol. 2006;1:8–18. PubMed

Patel A. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40. PubMed

The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72. PubMed

Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptide (BNP, NT-proBNP) measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411–8. PubMed PMC

Mayer O, Simon J, Plásková M, Cífková R, Trefil L. N-terminal pro-Brain natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifested heart failure. Eur J Epidemiol. 2009;24:363–8. PubMed

Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J. 2007;28:1374–81. PubMed

Sipilä K, Moilanen L, Nieminen T, et al. Metabolic syndrome and carotid intima media thickness in the Health 2000 survey. Atherosclerosis. 2009;204:276–81. PubMed

Allison MA, Wright CM. Age and gender are the strongest clinical correlates of prevalence of coronary calcification. Int J Cardiol. 2005;98:325–30. PubMed

Hunt ME, O’Malley PG, Feuerstein I, Taylor AJ. The relationship between the ‘metabolic score’ and sub-clinical atherosclerosis detected with electron beam computed tomography. Coron Artery Dis. 2003;14:317–22. PubMed

Meigs JB, Larson MG, D’Agostino RB, et al. Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study. Diab Care. 2002;25:1313–9. PubMed

LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162:421–9. PubMed

Uretsky S, Rozanski A, Singh P et al. The presence, characterization and prognosis of coronary plaques among patients with zero coronary calcium scores. Int J Cardiovasc Imaging. 2010; doi:10.1007/s10554-010-9730-0. PubMed

Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipidlowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation. 2006;113:427–37. PubMed

McEvoy JW, Blaha MJ, Defilippis AP, et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol. 2010;56:1613–22. PubMed

Ramakrishna G, Miller TD, Breen JF, Araoz PA, Hodge DO, Gibbons RJ. Relationship and prognostic value of coronary artery calcification by electron beam computed tomography to stress-induced ischemia by single photon emission computed tomography. Am Heart J. 2007;153:807–14. PubMed

Rasmussen-Torvik LJ, Li M, Kao W, et al. Association of a fasting glucose genetic risk score with subclinical atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes. 2011;60:331–5. PubMed PMC

Pechlivanis S, Scherag A, Mühleisen TW, et al. Heinz Nixdorf Recall Study Group. Coronary artery calcification and its relationship to validated genetic variants for diabetes mellitus assessed in the Heinz Nixdorf recall cohort. Arterioscler Thromb Vasc Biol. 2010;30:1867–72. PubMed